MATRIX PHARMACEUTICALS ApS: Financial statements 2014
CVR: 29625867
Source: annual report 2014, Danish Business Authority
01/01/2014 – 31/12/2014
MATRIX PHARMACEUTICALS ApS (CVR 29625867) has filed annual accounts for 2014. In 2014, the company reported a gross profit of DKK 928,617 and a net result of DKK 753,731 compared with DKK 961,193 the year before. That is a decrease of 19.4% compared with the year before. Equity in the 2014 report amounted to DKK 586,588. The solvency ratio was 13%.
- Gross Profit
- DKK 928,617
- Profit/Loss
- DKK 753,731
- Equity
- DKK 586,588
- Total Assets
- DKK 4,516,152
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2014 | - | 929 t. | 754 t. | 587 t. | - |
| 2013 | 8.6 mio. | 1.2 mio. | 961 t. | -167 t. | - |
| 2012 | 4.5 mio. | 264 t. | 79 t. | -1.1 mio. | - |
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningEvents in 2014
MATRIX PHARMACEUTICALS ApS has published its annual report for 2013. Revenue came to DKK 8,648,304, and the net result was DKK 961,193.
As of May 31, 2014, PRICEWATERHOUSECOOPERS STATSAUTORISERET REVISIONSPARTNERSELSKAB has stepped down as auditor of MATRIX PHARMACEUTICALS ApS.
As of January 21, 2014, Steen Larsen has joined the board of directors of MATRIX PHARMACEUTICALS ApS.
As of January 21, 2014, Mariann Florin Skafte has left the board of directors of MATRIX PHARMACEUTICALS ApS.
About MATRIX PHARMACEUTICALS ApS
MATRIX PHARMACEUTICALS ApS is a Danish company of the type Anpartsselskab based in København Ø, founded in 2006. The company is registered under the industry Engroshandel med medicinalvarer og sygeplejeartikler. The management consists of Karsten Høilund Skafte. The board consists of Karsten Høilund Skafte. The company is owned by Karsten Høilund Skafte and KHS HOLDING ApS. The company has 1 employee (2018). In 2025, the company reported revenue of DKK 1,090,380 and a net result of DKK 589,123 compared with DKK 440,028 the year before. Equity in the 2025 report amounted to DKK 589,123.